Media Articles Related to Magnevist (Gadopentetate)
New Considerations in HIV Care Diagnostics
Source: Medscape HIV/AIDS Headlines [2015.01.20]
Dr Benjamin Young highlights the recently announced UNAIDS Fast-track Cities program and reviews two new studies on HIV diagnostics.
Sepsis diagnostic quickly IDs most lethal form of sepsis
Source: Blood / Hematology News From Medical News Today [2015.01.15]
T2 Biosystems, a company developing innovative diagnostic products to improve patient health, today announced that results from its pivotal trial evaluating its lead products, the T2Candida Panel...
New diagnostic test for bowel diseases
Source: Irritable-Bowel Syndrome News From Medical News Today [2014.03.31]
A novel method for distinguishing different types of bowel disease using the stool samples of patients has been created by a group of researchers in the UK.
Heart attack diagnoses 'could be doubled' by gender-specific tests
Source: Cardiovascular / Cardiology News From Medical News Today [2015.01.22]
Researchers find that using a new high-sensitivity blood test with gender-specific diagnostic thresholds could improve the rate of heart attack diagnosis among women.
VolitionRX begins first ovarian cancer detection study to evaluate blood-based test
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.01.22]
VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, has announced it has signed an agreement to...
Published Studies Related to Magnevist (Gadopentetate)
Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MR imaging (DETECT Trial). [2011.02]
PURPOSE: To intraindividually compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast material-enhanced breast magnetic resonance (MR) imaging by using a prospective, multicenter double-blind, randomized protocol... CONCLUSION: Gadobenate dimeglumine is superior to gadopentetate dimeglumine for breast cancer diagnosis. (c) RSNA, 2010 Clinical trial registration no. NCT00486473 (http://www.clinicaltrials.gov/). Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.10100968/-/DC1.
Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. [2010.06]
PURPOSE: To prospectively compare the image quality and diagnostic performance achieved with doses of gadobenate dimeglumine and gadopentetate dimeglumine of 0.1 mmol per kilogram of body weight in patients undergoing contrast material-enhanced magnetic resonance (MR) angiography of the pelvis, thigh, and lower-leg (excluding foot) for suspected or known peripheral arterial occlusive disease... CONCLUSION: Higher-quality vessel visualization, greater contrast enhancement, fewer technical failures, and improved diagnostic performance are obtained with gadobenate dimeglumine, relative to gadopentetate dimeglumine, when compared intraindividually at 0.1-mmol/kg doses in patients undergoing contrast-enhanced MR angiography for suspected peripheral arterial occlusive disease. Copyright RSNA, 2010
Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. [2009.10]
CONCLUSION: At equal gadolinium dosage, gadobutrol appears to offer significant advantages over gadopentetate dimeglumine for the visualization of brain metastases, with particular benefit for improving the conspicuity of detected lesions.
Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla. [2009.04]
PURPOSE: To prospectively compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MRI of brain lesions at 3 Tesla (T)... CONCLUSION: Brain lesion depiction at 3T is significantly improved with 0.1 mmol/kg gadobenate dimeglumine.
Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial. [2009.03]
CONCLUSION: This study documents evidence for the noninferiority of a single i.v. bolus injection of 1.0 M gadobutrol (0.1 mmol/kg body weight) to 0.5 M gadopentetate (0.1 mmol/kg body weight) in the diagnostic assessment of liver lesions with contrast-enhanced MRI. The known excellent safety profile of gadobutrol was confirmed in this clinical trial and is similar to that of gadopentetate.
Clinical Trials Related to Magnevist (Gadopentetate)
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI [Recruiting]
This research is being done to find out if using the contrast agent MultiHance can be used
to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial
MultiHance is approved by the Food and Drug Administration (FDA) for use as a contrast
material for Magnetic Resonance Imaging (MRI) scans of the central nervous system. It is
believed that using MultiHance may be able to help doctors tell normal liver cells apart
from active tumor and from tumor affected by the chemotherapy. In this way, MultiHance may
improve the way patients with hepatocellular carcinoma are managed clinically.
We hypothesize that the Multi-Hance contrast material will provide better image definition
of treated liver tumor(s) on MRI imaging in comparison to other commercially available
Gadobutrol Magnevist-controlled Body Study [Recruiting]
The purpose of the study is to look at the safety (what are the side effects) and efficacy
(how well does it work) of gadobutrol when used for taking MR images of the body/extremities
regions. The results of the MRI with gadobutrol injection will be compared to the results
of MR images taken without contrast and with the results of the MR images taken with
Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries [Recruiting]
To compare two gadolinium contrast agents in terms of global paired diagnostic preference
(primary endpoint) for the assessment of contrast-enhanced MR Angiography of the carotid,
renal/abdominal and peripheral arteries
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist [Recruiting]
Assess potential risk for NSF in subjects with renal impairment (moderate) post magnevist
injection. Subjects will be screened within 48 hours of previously scheduled MRI, those
meeting the enrollment criteria will be enrolled prior to MRI and followed for 2 years post
MRI with visits occuring at 1yr and 2 yr timepoints, in addition follow-up phone calls
conducted at 1, 3, 6 and 18 months to assess for skin changes suggestive of NSF.
Safety and Efficacy Evaluation of DOTAREM´┐Ż in MRI of Central Nervous System (CNS) Lesions [Recruiting]
The purpose of this study is to look at the safety (what are the side effects)and efficacy
(how well does it work) of Dotarem« when used in taking images of the brain / spine. The
results will be compared to the results of MRI taken without Dotarem.
Reports of Suspected Magnevist (Gadopentetate) Side Effects
Nephrogenic Systemic Fibrosis (284),
Skin Induration (158),
Mobility Decreased (134),
Skin Tightness (125),
Oedema Peripheral (122),
Emotional Distress (118),
Skin Hypertrophy (110), more >>